Holen Sie sich die Stockscreener-App
4.10
2.50%
0.10
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
Intensity (INTS) Results Review: EPS Comes in Above Forecast in the Current Update - vinanet.vn
H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
H.C. Wainwright reiterates Buy on Intensity Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Intensity Therapeutics stock - Investing.com
INTS Stock Price, Quote & Chart - ChartMill
INTENSITY THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $7 FROM $5 - Bitget
INTS Maintained by HC Wainwright & Co. -- Price Target Raised to $7.00 - GuruFocus
H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Intensity Therapeutics (INTS) Dips 1% to $3.96, Trading Range Holds with Support at $3.76Zero Lag EMA - Vinanet
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com UK
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Intensity Therapeutics Warns of Substantial Doubt - Minichart
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade
INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView
Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView
Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus
Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView
Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView
INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView
BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView
INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView
BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView
Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Stock News Today - TradingKey
INTS Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Rise 1.64%Management Tone Analysis - vinanet.vn
Intensity Therapeutics (INTS.US) will release its earnings report before the market opens on August 11. - Moomoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
INTS Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
INTS|Intensity Therapeutics Inc|Price:3.960|Chg%:-0.040 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesFinancial Data - vinanet.vn
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):